Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | FABP4 | P15090 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743955 | 0.88 | HTR6 (0.84) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL422890 | 0.88 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL30229563 | 0.88 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL18867941 | 0.85 | HTR6 (0.56) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL3226178 | 0.85 | HTR6 (0.56) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL5972107 | 0.85 | HTR6 (0.55) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL1972911 | 0.84 | HTR6 (0.50) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL20841427 | 0.83 | HTR6 (0.63) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL1996380 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 | |
| SCHEMBL4099158 | 0.81 | HTR6 (0.68) | HTR6MEN1KMT2AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-111108105-B | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111225915-B | Imidazopyridine compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-100363347-C | 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER REC TECH LTD (GB) | 2008-01-23 | — | — | CN | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| US-7307099-B2 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-11 | — | — | US | disclosed |
| CN-1860112-A | 3-amino chroman and 2-amino tetralin derivatives | WYETH CORP (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1651637-A1 | 3-AMINO CHROMAN AND 2-AMINO TETRALIN DERIVATIVES | Wyeth (US) | 2006-05-03 | — | — | EP | disclosed |
| CN-1717233-A | 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | CANCER REC TECH LTD (GB) | 2006-01-04 | — | — | CN | disclosed |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | WYETH (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2005012291-A1 | 3-AMINO CHOMAN AND 2-AMINO TETRALIN DERIVATIVES | WYETH (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100265-A1 | 4-(1-(sulfonyl)-1h-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents | TXNRD1, TXNRD3, TXNRD2 | HTR6 1460/4885MEN1 4263/4885KMT2A 2448/4885 |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | HTR6 3579/4885MEN1 1694/4885KMT2A 2728/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | HTR6 4072/4885MEN1 8/4885KMT2A 246/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | HTR6 4105/4885MEN1 3281/4885KMT2A 1220/4885 |
| US-20050032873-A1 | 3-Amino chroman and 2-amino tetralin derivatives | TPH2, HTR2C, HTR7 | HTR6 8/4885MEN1 2139/4885KMT2A 1963/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | HTR6 4105/4885MEN1 3281/4885KMT2A 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.